This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Wed Jun 10, 6:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX) with bullish sentiments.

Introducing TipRanks MCP for Agents

Gilead Sciences (GILD)

Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Monday at $128.10.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 14.3% and a 43.1% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $160.11 average price target, which is a 23.1% upside from current levels. In a report issued on May 26, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

See today’s best-performing stocks on TipRanks >>

Jazz Pharmaceuticals (JAZZ)

Truist Financial analyst Joon Lee initiated coverage with a Buy rating on Jazz Pharmaceuticals today and set a price target of $256.00. The company’s shares closed last Monday at $232.04.

According to TipRanks.com, Lee is a 5-star analyst with an average return of 33.2% and a 55.3% success rate. Lee covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Vertex Pharmaceuticals, and Voyager Therapeutics. ;'>

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $258.85, representing a 9.2% upside. In a report issued on June 2, J.P. Morgan also maintained a Buy rating on the stock.

Argenx Se (ARGX)

Truist Financial analyst Danielle Brill maintained a Buy rating on Argenx Se today. The company’s shares closed last Monday at $882.41.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 12.3% and a 53.1% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Rapport Therapeutics, Inc., and Praxis Precision Medicines. ;'>

Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $1043.95, implying a 17.7% upside from current levels. In a report issued on June 6, TipRanks – xAI also upgraded the stock to Buy with a $969.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).